Corrigendum to "AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomes" [Experimental Hematology 2017;45:36-44]

Affiliations

• ¹ Crown Bioscience, Inc., Santa Clara, CA, USA.
• ² Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
• ³ State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China.
• ⁴ Crown Bioscience, Inc., Santa Clara, CA, USA; State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China.